الفهرس 
INTRODUCITONOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
Primary pediatric bone tumors are very rare neoplasms and account for approximately 6% of all childhood cancers. Osteosarcoma and The Ewing sarcoma family of tumors are the two most common pediatric bone malignancies accounting for 56% and 34% respectively. Others such as chondrosarcoma (6%) are rarely seen in skeletally immature patients.
The aim of our study was to evaluate treatment outcomes and prognostic factors in patients with primary pediatric malignancies treated at Alexandria clinical oncology department, in Alexandria University Hospital, and Borg El-Arab University Hospital in Egypt.
Our study was a retrospective study, one hundred and sixty-one cases from January 2010 to December 2019 were retrieved from Files, clinical characteristics and treatment outcomes were recorded.
Osteosarcoma accounted for the majority of the cases 50% (n=77) followed by Ewing sarcoma 48.7% (n=75) and the least common was chondrosarcoma 1.3% (n=2). Both osteosarcoma and Ewing’s sarcoma had a slight male predominance, 57.1% (n=44) and 61.3% (n=46) respectively. Pain was the most common presenting symptom in both tumors.
The 5-year overall survival for both localized and metastatic osteosarcoma was 63.2%. Patients who presented with localized osteosarcoma had a 5-year overall survival of 75.8% while those who presented metastatic disease had a 5-year overall survival of 38.2%, this was statistically significant with a p-value of 0.016. The most common site for metastasis was the lungs, accounting for 66.71% (n=24) of the metastatic sites, followed by spread to other bones 22.2% (n=8). Through a univariate analysis the following factors were found to have an impact on disease progression and patients’ survival; Age, tumor size, percentage of necrosis, type of surgery, and metastatic disease at presentation. Only the type of surgery had significance both in terms of Event Free Survival and overall survival. Metastatic disease at presentation and percentage of necrosis were significant when overall survival was assessed.
Patients with Ewing sarcoma